Contribution of18Fluorodeoxyglucose positron emission tomography uptake and TTF-1 expression in the evaluation of the EGFR mutation in patients with lung adenocarcinoma

Value of 18F-FDG uptake on PET/CT and CEA level to predict epidermal growth factor receptor mutations in pulmonary adenocarcinoma

(2014) Kai-Hsiung Ko et al.   EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING

Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012

(2014) Jacques Ferlay et al.   INTERNATIONAL JOURNAL OF CANCER

International trends in lung cancer incidence by histological subtype: Adenocarcinoma stabilizing in men but still increasing in women

(2014) J. Lortet-Tieulent et al.   LUNG CANCER

The Relationship between TTF-1 Expression and EGFR Mutations in Lung Adenocarcinomas

(2014) Wan Shanzhi et al.   PLoS One

NKX2-1/TITF1/TTF-1-Induced ROR1 Is Required to Sustain EGFR Survival Signaling in Lung Adenocarcinoma

(2012) Tomoya Yamaguchi et al.   CANCER CELL

High Incidence of EGFR Mutations in Korean Men Smokers with No Intratumoral Heterogeneity of Lung Adenocarcinomas: Correlation with Histologic Subtypes, EGFR/TTF-1 Expressions, and Clinical Features

(2012) Ping-Li Sun et al.   Journal of Thoracic Oncology

Rapid and Efficient Detection of EGFR Mutations in Problematic Cytologic Specimens by High-Resolution Melting Analysis

(2012) Katarina Hlinkova et al.   Molecular Diagnosis & Therapy

Early [18F]Fluorodeoxyglucose Positron Emission Tomography at Two Days of Gefitinib Treatment Predicts Clinical Outcome in Patients with Adenocarcinoma of the Lung

(2011) R. Takahashi et al.   CLINICAL CANCER RESEARCH

American Society of Clinical Oncology Provisional Clinical Opinion: Epidermal Growth Factor Receptor (EGFR) Mutation Testing for Patients With Advanced Non–Small-Cell Lung Cancer Considering First-Line EGFR Tyrosine Kinase Inhibitor Therapy

(2011) Vicki Leigh Keedy et al.   JOURNAL OF CLINICAL ONCOLOGY

Role of 18F-Fluorodeoxyglucose Positron Emission Tomography in Predicting Epidermal Growth Factor Receptor Mutations in Non-Small Cell Lung Cancer

(2011) R. H. Mak et al.   ONCOLOGIST

The IASLC Lung Cancer Staging Project: Proposals for the Inclusion of Broncho-Pulmonary Carcinoid Tumors in the Forthcoming (Seventh) Edition of the TNM Classification for Lung Cancer

(2010) William D. Travis et al.   Journal of Thoracic Oncology

Fluorodeoxyglucose positron emission tomography and tumor marker expression in non–small cell lung cancer

(2009) Matthew D. Taylor et al.   JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY

Relationship between primary lesion FDG uptake and clinical stage at PET–CT for non-small cell lung cancer patients: An observation

(2009) Minghuan Li et al.   LUNG CANCER

18F-FDG uptake and EGFR mutations in patients with non-small cell lung cancer: A single-institution retrospective analysis

(2009) Im Il Na et al.   LUNG CANCER

Correlation of F-18 fluorodeoxyglucose-positron emission tomography maximal standardized uptake value and EGFR mutations in advanced lung adenocarcinoma

(2009) Chun-Ta Huang et al.   MEDICAL ONCOLOGY

Survival of Cancer Cells Is Maintained by EGFR Independent of Its Kinase Activity

(2008) Zhang Weihua et al.   CANCER CELL

EGFR Mutations Predict Survival Benefit From Gefitinib in Patients With Advanced Lung Adenocarcinoma: A Historical Comparison of Patients Treated Before and After Gefitinib Approval in Japan

(2008) Toshimi Takano et al.   JOURNAL OF CLINICAL ONCOLOGY

Tumor Cell Metabolism Imaging

(2008) C. Plathow et al.   JOURNAL OF NUCLEAR MEDICINE

Causes and Consequences of Increased Glucose Metabolism of Cancers

(2008) R. J. Gillies et al.   JOURNAL OF NUCLEAR MEDICINE

Relationship Between Non-small Cell Lung Cancer FDG Uptake at PET, Tumor Histology, and Ki-67 Proliferation Index

(2008) Hubert Vesselle et al.   Journal of Thoracic Oncology

Usefulness of FDG-PET for early prediction of the response to gefitinib in non-small cell lung cancer

(2007) Noriaki Sunaga et al.   LUNG CANCER